Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc

Abstract

Abstract c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.

Keywords

• Oncogene
• Transcription
• Leucine zipper
• Peptide
• Protein-protein interaction